OR WAIT null SECS
January 29, 2009
Also, UCB will divest certain business in emerging markets to GSK; the KineMatik Group named Michael G. Jarjour president and CEO; more...
January 22, 2009
Also, Elan explores strategic alternatives; NanoGuardian appoints John D. Glover to lead its Security Advisory Board; more...
January 15, 2009
Also, Bristol-Myers Squibb forms collaboration with ZymoGenetics, Hana Biosciences appoints VP of regulatory affairs, more...
January 08, 2009
Also, Novozymes Biologicals settles pollution case with the US Department of Justice; EntreMed restructures management team; more...
January 07, 2009
Outsourcing sterile manufacturing involves an integrated approach in product life-cycle management.
January 02, 2009
The incoming administration has renewed hope for stem cells, but less adequate copycats may follow.
A book explains the many pharmaceutical applications of polymers from natural sources.
Instead of hampering progress, cost pressures might inspire Big Pharma to get creative.
January 01, 2009
A new excipient for orally disintegrating tablets not only imparts superior tablet characteristics, but has the added advantage of allowing users to maintain full control over their formulations, manufacturing processes and intellectual property.
Hot-melt extrusion offers many advantages compared with conventional solid dosage form manufacturing, and has consequently received considerable attention from both the pharmaceutical industry and academia as a novel drug delivery technology. The possibility of forming solid dispersions with improved bioavailability renders hot-melt extrusion an excellent alternative to other conventionally employed techniques.